UNSPSC 51102813: Allantoin/aminacrine/sulfisoxazole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.

UNSPSC 51102813 Allantoin/aminacrine/sulfisoxazole is a Commodity code that in recent state and local procurement activity encompasses pharmaceuticals and medical supplies far broader than its nominal ingredient list — naloxone, generic multi-source pharmaceuticals, over-the-counter products, and emergency medical consumables including cardiac monitoring equipment, respiratory devices, and bandaging materials. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, municipal fire departments, and cooperative purchasing alliances serving multiple jurisdictions. The scope ranges from direct manufacturer relationships and pharmacy benefit program administration to tactical procurement of high-volume medical supplies for emergency response operations, indicating that the code serves both strategic supply-chain work and routine commodity acquisition across health and safety functions.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a due date of July 26, 2023. The City of Tampa issued ITB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a due date of March 13, 2026, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and effectiveness set for July 1, 2026.